Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics Incorporated is offering senior unsecured notes under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement describes the notes’ general terms including semiannual interest, optional redemption (including a Par Call Date provision), and a Change of Control repurchase right at 101% of principal plus accrued interest. Net proceeds are expected to be used for general corporate purposes and may include repayment of the Company’s $500 million 3.45% Senior Notes due June 1, 2026. The notes will rank equally with Quest Diagnostics’ other senior unsecured obligations and be structurally subordinated to subsidiary indebtedness. The prospectus incorporates by reference the Company’s 2025 Form 10-K risk factors and other filings.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share. After this award, he holds 33,376 shares directly.
Footnotes state the transaction represents an award of restricted share units and reflects shares acquired through a dividend reinvestment plan administered by his broker, which he chose to report early rather than on a later Form 5.
Quest Diagnostics senior executive Patrick Plewman, SVP for Diagnostic Services, reported a small acquisition of company common stock. On April 20, 2026, he acquired 49 shares at $194.699 per share through a dividend reinvestment plan administered by his broker.
Following this transaction, Plewman directly holds 15,247 Quest Diagnostics shares. The filing notes that these dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report the acquisition early on this Form 4.
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 7 shares of common stock at $194.699 per share, bringing his direct holdings to 2,711 shares.
The shares were acquired automatically under a broker-administered dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Carter chose to report this routine transaction early on Form 4.
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.
Quest Diagnostics SVP Karthik Kuppusamy reported a small acquisition of 39 shares of common stock at $194.699 per share. The filing describes this as a small acquisition under Rule 16a-6 related to a dividend reinvestment plan. Following the transaction, he holds 13,490 shares directly, plus indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition. On April 20, 2026, he acquired 37 shares of Quest Diagnostics common stock at $194.696 per share through a dividend reinvestment plan under Rule 16a-6. Following this transaction, he directly holds 11,901 common shares.
Quest Diagnostics grew solidly in early 2026. Net revenues for the quarter ended March 31, 2026 rose to $2,895 million from $2,652 million, driven mainly by its core diagnostic information services business.
DIS revenue increased 9.4% to $2,832 million as requisition volume grew 10.9%, helped by new relationships with Corewell Health and Fresenius Medical Care. Revenue per requisition fell 1.3% due to a higher mix of routine testing, but excluding these contracts it increased about 2.5%.
Net income attributable to Quest Diagnostics rose to $252 million from $220 million, and diluted EPS increased to $2.24 from $1.94. Operating income improved to $399 million from $346 million as cost savings from the Invigorate program helped offset higher compensation and supplies. Operating cash flow was $278 million versus $314 million, reflecting timing of receipts and higher bonus payments. The company invested $114 million in capital expenditures, continued a quarterly dividend of $0.86 per share, and ended the quarter with $393 million of cash and $5.2 billion of long-term debt.
Quest Diagnostics reported strong first quarter 2026 results and raised its full year 2026 outlook. Net revenues were $2.90 billion, up 9.2% from 2025, with Diagnostic Information Services revenues up 9.4%. Reported diluted EPS increased to $2.24, up 15.5%, while adjusted diluted EPS rose to $2.50, up 13.1%, reflecting improved profitability.
Operating income grew to $399 million, with adjusted operating margin edging up to 15.4% of net revenues. Cash provided by operations was $278 million, compared to $314 million a year earlier, while capital expenditures were $114 million. The company highlighted double-digit growth in Advanced Diagnostics and strong consumer-channel performance.
For full year 2026, Quest now expects net revenues of $11.78–$11.90 billion and reported diluted EPS of $9.58–$9.78. Adjusted diluted EPS is projected at $10.63–$10.83, above prior guidance, supported by solid first quarter execution and ongoing strategic initiatives.